ATE372379T1 - Hybride and einzelkettige meganukleasen und deren anwendungen - Google Patents

Hybride and einzelkettige meganukleasen und deren anwendungen

Info

Publication number
ATE372379T1
ATE372379T1 AT03744485T AT03744485T ATE372379T1 AT E372379 T1 ATE372379 T1 AT E372379T1 AT 03744485 T AT03744485 T AT 03744485T AT 03744485 T AT03744485 T AT 03744485T AT E372379 T1 ATE372379 T1 AT E372379T1
Authority
AT
Austria
Prior art keywords
rare
hybrid
polynucleotide sequences
cutting endonucleases
cutting
Prior art date
Application number
AT03744485T
Other languages
English (en)
Inventor
Sylvain Arnould
Patrick Chames
Andre Choulika
Jean-Charles Epinat
Emmanuel Lacroix
Original Assignee
Cellectis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=28041871&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE372379(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Cellectis filed Critical Cellectis
Application granted granted Critical
Publication of ATE372379T1 publication Critical patent/ATE372379T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Detergent Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT03744485T 2002-03-15 2003-03-14 Hybride and einzelkettige meganukleasen und deren anwendungen ATE372379T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US36411302P 2002-03-15 2002-03-15

Publications (1)

Publication Number Publication Date
ATE372379T1 true ATE372379T1 (de) 2007-09-15

Family

ID=28041871

Family Applications (1)

Application Number Title Priority Date Filing Date
AT03744485T ATE372379T1 (de) 2002-03-15 2003-03-14 Hybride and einzelkettige meganukleasen und deren anwendungen

Country Status (10)

Country Link
US (2) US20060078552A1 (de)
EP (1) EP1485475B2 (de)
JP (3) JP2005520519A (de)
AT (1) ATE372379T1 (de)
AU (1) AU2003215869B2 (de)
CA (1) CA2479153C (de)
DE (1) DE60316124T3 (de)
DK (1) DK1485475T3 (de)
ES (1) ES2292994T3 (de)
WO (1) WO2003078619A1 (de)

Families Citing this family (151)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009095742A1 (en) * 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
US20100151556A1 (en) * 2002-03-15 2010-06-17 Cellectis Hybrid and single chain meganucleases and use thereof
US20060078552A1 (en) * 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
JP4966006B2 (ja) 2003-01-28 2012-07-04 セレクティス カスタムメイドメガヌクレアーゼおよびその使用
EP1591521A1 (de) * 2004-04-30 2005-11-02 Cellectis I-Dmo I -Derivate mit erhöhter Aktivität bei 37 Grad C und deren Verwendung
WO2007034262A1 (en) * 2005-09-19 2007-03-29 Cellectis Heterodimeric meganucleases and use thereof
AU2006224248B2 (en) * 2005-03-15 2011-01-06 Cellectis I-Crei meganuclease variants with modified specificity, method of preparation and uses thereof
WO2007014275A2 (en) * 2005-07-26 2007-02-01 Sangamo Biosciences, Inc. Targeted integration and expression of exogenous nucleic acid sequences
EP2484758B1 (de) 2005-10-18 2013-10-02 Precision Biosciences Rational konstruierte Meganukleasen mit veränderter Sequenzspezifität und DNA-Bindungsaffinität
WO2007060495A1 (en) 2005-10-25 2007-05-31 Cellectis I-crei homing endonuclease variants having novel cleavage specificity and use thereof
WO2007049095A1 (en) 2005-10-25 2007-05-03 Cellectis Laglidadg homing endonuclease variants having mutations in two functional subdomains and use thereof
WO2008010009A1 (en) * 2006-07-18 2008-01-24 Cellectis Meganuclease variants cleaving a dna target sequence from a rag gene and uses thereof
WO2008093152A1 (en) * 2007-02-01 2008-08-07 Cellectis Obligate heterodimer meganucleases and uses thereof
CN101784664B (zh) 2007-06-01 2013-04-10 Omt公司 用于抑制内源性免疫球蛋白基因和生产转基因人独特型抗体的组合物和方法
US20140112904A9 (en) 2007-06-06 2014-04-24 Cellectis Method for enhancing the cleavage activity of i-crei derived meganucleases
WO2008149176A1 (en) * 2007-06-06 2008-12-11 Cellectis Meganuclease variants cleaving a dna target sequence from the mouse rosa26 locus and uses thereof
CA2691440A1 (en) 2007-06-29 2009-01-08 Pioneer Hi-Bred International, Inc. Methods for altering the genome of a monocot plant cell
WO2009013559A1 (en) 2007-07-23 2009-01-29 Cellectis Meganuclease variants cleaving a dna target sequence from the human hemoglobin beta gene and uses thereof
WO2009019528A1 (en) * 2007-08-03 2009-02-12 Cellectis Meganuclease variants cleaving a dna target sequence from the human interleukin-2 receptor gamma chain gene and uses thereof
US11235026B2 (en) 2007-09-27 2022-02-01 Sangamo Therapeutics, Inc. Methods and compositions for modulating PD1
WO2009042163A2 (en) * 2007-09-27 2009-04-02 Sangamo Biosciences, Inc. Rapid in vivo identification of biologically active nucleases
US8563314B2 (en) 2007-09-27 2013-10-22 Sangamo Biosciences, Inc. Methods and compositions for modulating PD1
EP3098309B1 (de) * 2007-10-31 2019-04-10 Precision Biosciences, Inc. Rational konstruierte einzelketten-meganukleasen mit nicht-palindrom-erkennungssequenzen
AU2015201270B2 (en) * 2007-10-31 2017-01-19 Precision Biosciences, Inc. Rationally-designed single-chain meganucleases with non-palindromic recognition sequences
AU2008335324A1 (en) * 2007-12-07 2009-06-18 Precision Biosciences, Inc. Rationally-designed meganucleases with recognition sequences found in DNase hypersensitive regions of the human genome
WO2009074842A1 (en) * 2007-12-13 2009-06-18 Cellectis Improved chimeric meganuclease enzymes and uses thereof
WO2009114321A2 (en) * 2008-03-11 2009-09-17 Precision Biosciencs, Inc. Rationally-designed meganucleases for maize genome engineering
US20100071083A1 (en) * 2008-03-12 2010-03-18 Smith James J Temperature-dependent meganuclease activity
CA2722797A1 (en) * 2008-04-28 2009-11-05 Precision Biosciences, Inc. Fusion molecules of rationally-designed dna-binding proteins and effector domains
ES2625941T3 (es) 2008-07-14 2017-07-21 Precision Biosciences, Inc. Secuencias de reconocimiento para meganucleasas derivadas de i-crei y sus usos
EP2352821B1 (de) * 2008-09-08 2016-11-23 Cellectis Eine dna-zielsequenz aus einem glutamin-synthetase-gen spaltende meganuklease-varianten und verwendungen dafür
EP2180058A1 (de) 2008-10-23 2010-04-28 Cellectis Meganuklease-Rekombinationssystem
EP2208785A1 (de) 2009-01-15 2010-07-21 Newbiotechnic, S.A. Verfahren und Kits zum Erzeugen von miRNA- und smallRNA-Expressionsvektoren und ihre Anwendung zur Entwicklung von lentiviralen Expressionsbibliotheken
US20110294217A1 (en) * 2009-02-12 2011-12-01 Fred Hutchinson Cancer Research Center Dna nicking enzyme from a homing endonuclease that stimulates site-specific gene conversion
JP5932632B2 (ja) 2009-03-20 2016-06-15 サンガモ バイオサイエンシーズ， インコーポレイテッド 改変された亜鉛フィンガータンパク質を使用したｃｘｃｒ４の修飾
WO2010122367A2 (en) * 2009-04-21 2010-10-28 Cellectis Meganuclease variants cleaving the genomic insertion of a virus and uses thereof
US8772008B2 (en) * 2009-05-18 2014-07-08 Sangamo Biosciences, Inc. Methods and compositions for increasing nuclease activity
WO2010136981A2 (en) 2009-05-26 2010-12-02 Cellectis Meganuclease variants cleaving the genome of a pathogenic non-integrating virus and uses thereof
AU2010266705B2 (en) * 2009-06-30 2014-06-05 Sangamo Therapeutics, Inc. Rapid screening of biologically active nucleases and isolation of nuclease-modified cells
WO2011007193A1 (en) 2009-07-17 2011-01-20 Cellectis Viral vectors encoding a dna repair matrix and containing a virion-associated site specific meganuclease for gene targeting
US9234016B2 (en) 2009-07-28 2016-01-12 Sangamo Biosciences, Inc. Engineered zinc finger proteins for treating trinucleotide repeat disorders
AU2010282958B2 (en) 2009-08-11 2015-05-21 Sangamo Therapeutics, Inc. Organisms homozygous for targeted modification
WO2011021062A1 (en) 2009-08-21 2011-02-24 Cellectis Meganuclease variants cleaving a dna target sequence from the human lysosomal acid alpha-glucosidase gene and uses thereof
WO2011036640A2 (en) 2009-09-24 2011-03-31 Cellectis Meganuclease reagents of uses thereof for treating genetic diseases caused by frame shift/non sense mutations
CN102762726A (zh) 2009-11-27 2012-10-31 巴斯夫植物科学有限公司 嵌合内切核酸酶及其用途
AU2010325563B2 (en) 2009-11-27 2017-02-02 Basf Plant Science Company Gmbh Chimeric endonucleases and uses thereof
CA2793596A1 (en) 2009-12-30 2011-07-07 Pioneer Hi-Bred International, Inc. Methods and compositions for targeted polynucleotide modification
WO2011095475A1 (en) * 2010-02-02 2011-08-11 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the diagnosis and therapy of retinitis pigmentosa
WO2011101696A1 (en) 2010-02-18 2011-08-25 Cellectis Improved meganuclease recombination system
EP2539445B1 (de) * 2010-02-26 2018-03-21 Cellectis Verwendung von endonukleasen für den einsatz von transgenen in safe-harbor-loci
CA2794037A1 (en) 2010-03-22 2011-09-29 Philip Morris Products S.A. Modifying enzyme activity in plants
US20130145487A1 (en) 2010-05-12 2013-06-06 Cellectis Meganuclease variants cleaving a dna target sequence from the dystrophin gene and uses thereof
EP2569435A1 (de) 2010-05-12 2013-03-20 Cellectis Eine dna-zielsequenz von einem rhodopsin-gen abspaltende meganukleasevarianten und ihre verwendung
AU2011256838B2 (en) 2010-05-17 2014-10-09 Sangamo Therapeutics, Inc. Novel DNA-binding proteins and uses thereof
WO2012001527A2 (en) 2010-06-15 2012-01-05 Cellectis S.A. Method for improving cleavage of dna by endonuclease sensitive to methylation
SG186932A1 (en) 2010-07-07 2013-02-28 Cellectis Meganucleases variants cleaving a dna target sequence in the nanog gene and uses thereof
WO2012010976A2 (en) 2010-07-15 2012-01-26 Cellectis Meganuclease variants cleaving a dna target sequence in the tert gene and uses thereof
WO2012007848A2 (en) 2010-07-16 2012-01-19 Cellectis Meganuclease variants cleaving a dna target sequence in the was gene and uses thereof
CA2807270A1 (en) 2010-08-02 2012-02-09 Cellectis Method for targeted genomic events in diatoms
CA2815512A1 (en) 2010-10-27 2012-05-03 Philippe Duchateau Method for increasing the efficiency of double-strand break-induced mutagenesis
US9044492B2 (en) 2011-02-04 2015-06-02 Cellectis Sa Method for modulating the efficiency of double-strand break-induced mutagenesis
EP2689019A2 (de) 2011-03-23 2014-01-29 Pioneer Hi-Bred International Inc. Verfahren zur herstellung eines komplexen transgenen trait locus
US20140115726A1 (en) 2011-04-05 2014-04-24 Cellectis New tale-protein scaffolds and uses thereof
WO2012138901A1 (en) 2011-04-05 2012-10-11 Cellectis Sa Method for enhancing rare-cutting endonuclease efficiency and uses thereof
EP2702160B1 (de) 2011-04-27 2020-05-27 Amyris, Inc. Verfahren zur genommodifikation
WO2012158778A1 (en) 2011-05-16 2012-11-22 Cellectis S.A. Doubly secure transgenic algae or cyanobacteria strains to prevent their establishment and spread in natural ecosystems
US9758796B2 (en) 2011-06-10 2017-09-12 Basf Plant Science Company Gmbh Nuclease fusion protein and uses thereof
CN104080914A (zh) 2011-06-21 2014-10-01 先锋国际良种公司 产生雄性不育植物的组合物和方法
EP2729567B1 (de) 2011-07-08 2016-10-05 Cellectis Verfahren zur erhöhung der wirkung einer doppelsträngigen bruchinduzierten mutagenese
EP2739739A1 (de) 2011-08-03 2014-06-11 E. I. Du Pont de Nemours and Company Verfahren und zusammensetzungen zur gezielten einführung in eine pflanze
CN108285491B (zh) 2012-02-29 2021-08-10 桑格摩生物科学股份有限公司 治疗亨廷顿氏病的方法和组合物
WO2013166113A1 (en) 2012-05-04 2013-11-07 E. I. Du Pont De Nemours And Company Compositions and methods comprising sequences having meganuclease activity
EP2877488B1 (de) 2012-07-24 2021-02-24 Cellectis Neue modulare basenspezifische nukleinsäurebindende domänen aus burkholderia-rhizoxinica-proteinen
EP2906684B8 (de) 2012-10-10 2020-09-02 Sangamo Therapeutics, Inc. T-zell-modifizierende verbindungen und verwendungen davon
CN105121649A (zh) 2012-11-16 2015-12-02 赛莱蒂克斯公司 靶向修饰藻基因组的方法
WO2014102688A1 (en) 2012-12-27 2014-07-03 Cellectis New design matrix for improvement of homology-directed gene targeting
RU2690352C2 (ru) 2013-02-20 2019-05-31 Регенерон Фармасютикалс, Инк. Генетическая модификация крыс
US10329574B2 (en) 2013-03-12 2019-06-25 E I Du Pont De Nemours And Company Methods for the identification of variant recognition sites for rare-cutting engineered double-strand-break-inducing agents and compositions and uses thereof
JP6873530B2 (ja) 2013-03-15 2021-05-19 イン3バイオ・リミテッドIn3Bio Ltd. 自己組織化合成タンパク質（Ｓｅｌｆ−Ａｓｓｅｍｂｌｉｎｇ Ｓｙｎｔｈｅｔｉｃ Ｐｒｏｔｅｉｎｓ）
JP6411463B2 (ja) 2013-04-16 2018-10-24 リジェネロン・ファーマシューティカルズ・インコーポレイテッドＲｅｇｅｎｅｒｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ラットゲノムの標的改変
CA2929179A1 (en) 2013-11-11 2015-05-14 Sangamo Biosciences, Inc. Htt genetic repressor, viral vector, and uses thereof
EP3460063B1 (de) 2013-12-11 2024-03-13 Regeneron Pharmaceuticals, Inc. Verfahren und zusammensetzungen zur gezielten modifikation eines genoms
RU2685914C1 (ru) 2013-12-11 2019-04-23 Регенерон Фармасьютикалс, Инк. Способы и композиции для направленной модификации генома
US9476065B2 (en) 2013-12-19 2016-10-25 Amyris, Inc. Methods for genomic integration
DK3083671T3 (da) 2013-12-20 2020-12-07 Hutchinson Fred Cancer Res Mærkede kimære effektormolekyler og receptorer deraf
US9624498B2 (en) 2014-03-18 2017-04-18 Sangamo Biosciences, Inc. Methods and compositions for regulation of zinc finger protein expression
PL3152312T3 (pl) 2014-06-06 2020-08-10 Regeneron Pharmaceuticals, Inc. Sposoby i kompozycje do modyfikowania docelowego locus
PT3155099T (pt) 2014-06-23 2018-04-20 Regeneron Pharma Montagem de dna mediada por nuclease
MX2016017317A (es) 2014-06-26 2017-08-24 Regeneron Pharma Metodos y composiciones para modificaciones geneticas dirigidas y metodos de uso.
US10428310B2 (en) 2014-10-15 2019-10-01 Regeneron Pharmaceuticals, Inc. Methods and compositions for generating or maintaining pluripotent cells
RU2707137C2 (ru) 2014-12-19 2019-11-22 Регенерон Фармасьютикалз, Инк. Способы и композиции для нацеленной генетической модификации посредством одноэтапного множественного нацеливания
ES2959608T3 (es) 2015-04-03 2024-02-27 Dana Farber Cancer Inst Inc Composición y métodos de edición del genoma de células B
US11827904B2 (en) 2015-04-29 2023-11-28 Fred Hutchinson Cancer Center Modified stem cells and uses thereof
CA3008413A1 (en) 2015-12-18 2017-06-22 Sangamo Therapeutics, Inc. Targeted disruption of the t cell receptor
EA201891212A1 (ru) 2015-12-18 2019-01-31 Сангамо Терапьютикс, Инк. Адресная дезорганизация клеточного рецептора гкгс
WO2017201311A2 (en) 2016-05-18 2017-11-23 Amyris, Inc. Compositions and methods for genomic integration of nucleic acids into exogenous landing pads
EP3490373B1 (de) 2016-07-29 2023-10-25 Regeneron Pharmaceuticals, Inc. Maüse mit mutationen, die in exprimierung vonc-truncated fibrillin-1 resultieren
EP3504327B1 (de) 2016-08-24 2021-10-06 Sangamo Therapeutics, Inc. Manipulierte zielspezifische nukleasen
BR112019005633A8 (pt) 2016-09-23 2023-04-11 Hutchinson Fred Cancer Res Tcrs específicos para antigênio ha-1 de histocompatibilidade (h) menor e usos dos mesmos
AU2018210420A1 (en) 2017-01-19 2019-08-08 Omniab, Inc. Human antibodies from transgenic rodents with multiple heavy chain immunoglobulin loci
EA201992131A1 (ru) 2017-03-15 2020-02-06 Фред Хатчинсон Кэнсер Рисерч Сентер Высокоаффинные специфичные к mage-a1 tcr и их применение
IL301115A (en) 2017-04-28 2023-05-01 Acuitas Therapeutics Inc New lipid carbonyl and lipid nanoparticle formulations for delivery of nucleic acids
CA3059793A1 (en) 2017-05-03 2018-11-08 Sangamo Therapeutics, Inc. Methods and compositions for modification of a cystic fibrosis transmembrane conductance regulator (cftr) gene
CA3064000A1 (en) 2017-05-24 2018-11-29 Effector Therapeutics, Inc. Methods and compositions for cellular immunotherapy
US11697822B2 (en) 2017-08-29 2023-07-11 KWS SAAT SE & Co. KGaA Blue aleurone and other segregation systems
AU2018327225A1 (en) 2017-09-06 2020-02-27 Fred Hutchinson Cancer Center Strep-tag specific chimeric receptors and uses thereof
WO2019051135A1 (en) 2017-09-06 2019-03-14 Fred Hutchinson Cancer Research Center METHODS FOR IMPROVING ADOPTIVE CELL THERAPY
AU2018338790B2 (en) 2017-09-29 2022-09-15 Regeneron Pharmaceuticals, Inc. Non-human animals comprising a humanized TTR locus and methods of use
US20210069241A1 (en) 2017-10-20 2021-03-11 Fred Hutchinson Cancer Research Center Compositions and methods of immunotherapy targeting tigit and/or cd112r or comprising cd226 overexpression
WO2019109047A1 (en) 2017-12-01 2019-06-06 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
WO2019140278A1 (en) 2018-01-11 2019-07-18 Fred Hutchinson Cancer Research Center Immunotherapy targeting core binding factor antigens
JP2021514631A (ja) 2018-02-26 2021-06-17 フレッド ハッチンソン キャンサー リサーチ センター 細胞免疫療法のための組成物および方法
US11690921B2 (en) 2018-05-18 2023-07-04 Sangamo Therapeutics, Inc. Delivery of target specific nucleases
WO2020018964A1 (en) 2018-07-20 2020-01-23 Fred Hutchinson Cancer Research Center Compositions and methods for controlled expression of antigen-specific receptors
WO2020041501A1 (en) 2018-08-22 2020-02-27 Fred Hutchinson Cancer Research Center Immunotherapy targeting kras or her2 antigens
EP3844266A1 (de) 2018-08-28 2021-07-07 Fred Hutchinson Cancer Research Center Verfahren und zusammensetzungen zur adoptiven t-zelltherapie unter einbeziehung von induzierter notch-signalisierung
CA3111711A1 (en) 2018-09-18 2020-03-26 Sangamo Therapeutics, Inc. Programmed cell death 1 (pd1) specific nucleases
WO2020068702A1 (en) 2018-09-24 2020-04-02 Fred Hutchinson Cancer Research Center Chimeric receptor proteins and uses thereof
MX2021005308A (es) 2018-11-09 2021-09-08 Fred Hutchinson Cancer Center Star Receptores de celulas t especificos para mesotelina y su uso en inmunoterapia.
KR20200071198A (ko) 2018-12-10 2020-06-19 네오이뮨텍, 인코퍼레이티드 Nrf2 발현 조절 기반 T 세포 항암면역치료법
JP7449291B2 (ja) 2018-12-20 2024-03-13 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヌクレアーゼ媒介リピート伸長
CN113474328A (zh) 2019-01-11 2021-10-01 爱康泰生治疗公司 用于脂质纳米颗粒递送活性剂的脂质
EP3927727A1 (de) 2019-02-20 2021-12-29 Fred Hutchinson Cancer Research Center Für ras-neoantigene spezifische bindungsproteine und deren verwendungen
CN113784978A (zh) 2019-03-11 2021-12-10 弗雷德哈钦森癌症研究中心 高亲合力wt1 t细胞受体及其用途
CN113795588A (zh) 2019-04-04 2021-12-14 瑞泽恩制药公司 用于在靶向性载体中无瘢痕引入靶向修饰的方法
SG11202108454RA (en) 2019-04-04 2021-09-29 Regeneron Pharma Non-human animals comprising a humanized coagulation factor 12 locus
KR20220016869A (ko) 2019-06-04 2022-02-10 리제너론 파마슈티칼스 인코포레이티드 베타-슬립 돌연변이를 갖는 인간화 ttr 좌위를 포함하는 비-인간 동물 및 사용 방법
MX2021015122A (es) 2019-06-07 2022-04-06 Regeneron Pharma Animales no humanos que comprenden un locus de albumina humanizado.
US20220409661A1 (en) 2019-08-20 2022-12-29 Fred Hutchinson Cancer Research Center T-cell immunotherapy specific for wt-1
WO2021108363A1 (en) 2019-11-25 2021-06-03 Regeneron Pharmaceuticals, Inc. Crispr/cas-mediated upregulation of humanized ttr allele
WO2022016070A1 (en) 2020-07-16 2022-01-20 Acuitas Therapeutics, Inc. Cationic lipids for use in lipid nanoparticles
EP4204545A2 (de) 2020-08-25 2023-07-05 Kite Pharma, Inc. T-zellen mit verbesserter funktionalität
JP2023542528A (ja) 2020-09-24 2023-10-10 フレッド ハッチンソン キャンサー センター Ｓｏｘ２抗原を標的とする免疫療法
WO2022066973A1 (en) 2020-09-24 2022-03-31 Fred Hutchinson Cancer Research Center Immunotherapy targeting pbk or oip5 antigens
TW202222841A (zh) 2020-10-06 2022-06-16 福瑞德哈金森腫瘤研究中心 用於治療表現mage-a1之疾病的組成物及方法
CA3201767A1 (en) 2020-12-14 2022-06-23 Thomas M. Schmitt Compositions and methods for cellular immunotherapy
WO2022240846A1 (en) 2021-05-10 2022-11-17 Sqz Biotechnologies Company Methods for delivering genome editing molecules to the nucleus or cytosol of a cell and uses thereof
WO2022251644A1 (en) 2021-05-28 2022-12-01 Lyell Immunopharma, Inc. Nr4a3-deficient immune cells and uses thereof
EP4347826A1 (de) 2021-06-02 2024-04-10 Lyell Immunopharma, Inc. Nr4a3-defiziente immunzellen und verwendungen davon
WO2023288281A2 (en) 2021-07-15 2023-01-19 Fred Hutchinson Cancer Center Chimeric polypeptides
WO2023014922A1 (en) 2021-08-04 2023-02-09 The Regents Of The University Of Colorado, A Body Corporate Lat activating chimeric antigen receptor t cells and methods of use thereof
IL311962A (en) 2021-10-14 2024-06-01 Lonza Sales Ag Producer cells are adapted to produce extracellular vesicles
WO2023081756A1 (en) 2021-11-03 2023-05-11 The J. David Gladstone Institutes, A Testamentary Trust Established Under The Will Of J. David Gladstone Precise genome editing using retrons
WO2023129974A1 (en) 2021-12-29 2023-07-06 Bristol-Myers Squibb Company Generation of landing pad cell lines
WO2023141602A2 (en) 2022-01-21 2023-07-27 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2023220603A1 (en) 2022-05-09 2023-11-16 Regeneron Pharmaceuticals, Inc. Vectors and methods for in vivo antibody production
WO2023225665A1 (en) 2022-05-19 2023-11-23 Lyell Immunopharma, Inc. Polynucleotides targeting nr4a3 and uses thereof
WO2024044723A1 (en) 2022-08-25 2024-02-29 Renagade Therapeutics Management Inc. Engineered retrons and methods of use
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US5006333A (en) * 1987-08-03 1991-04-09 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
FR2646438B1 (fr) * 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
US5272071A (en) * 1989-12-22 1993-12-21 Applied Research Systems Ars Holding N.V. Method for the modification of the expression characteristics of an endogenous gene of a given cell line
US5843701A (en) * 1990-08-02 1998-12-01 Nexstar Pharmaceticals, Inc. Systematic polypeptide evolution by reverse translation
US5641670A (en) * 1991-11-05 1997-06-24 Transkaryotic Therapies, Inc. Protein production and protein delivery
US6063630A (en) * 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US5436150A (en) 1992-04-03 1995-07-25 The Johns Hopkins University Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease
US20040019916A1 (en) * 1992-04-24 2004-01-29 Zarling David A. In vivo homologous sequence targeting in eukaryotic cells
US5474896A (en) 1992-05-05 1995-12-12 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
US6395959B1 (en) 1992-05-05 2002-05-28 Institut Pasteur Nucleotide sequence encoding the enzyme I SceI and the use thereof
US5792632A (en) 1992-05-05 1998-08-11 Institut Pasteur Nucleotide sequence encoding the enzyme I-SceI and the uses thereof
EP0682699B1 (de) 1993-02-12 2003-05-07 The Johns-Hopkins University FUNKTIONELLE DOMÄNEN DER RESTRIKTIONSENDONUKLEASEN AUS -i(FLAVOBAKTERIUM OKEANOKOITES)(FOKI)
US5801030A (en) * 1995-09-01 1998-09-01 Genvec, Inc. Methods and vectors for site-specific recombination
US5830729A (en) 1996-04-18 1998-11-03 Institut Pasteur I Sce I-induced gene replacement and gene conversion in embryonic stem cells
IL120241A0 (en) * 1997-02-17 1997-06-10 B G Negev Technologies And App DNA segments encoding a domain of ho-endonuclease
US6232112B1 (en) * 1997-11-24 2001-05-15 Flinders Technologies Pty Ltd Of Flinders University Reagents and methods for diversification of DNA
WO2000046385A1 (en) 1999-02-03 2000-08-10 The Children's Medical Center Corporation Gene repair involving in vivo excision of targeting dna
AU2982900A (en) 1999-02-03 2000-08-25 Children's Medical Center Corporation Gene repair involving the induction of double-stranded dna cleavage at a chromosomal target site
AU2001297625A1 (en) * 2000-12-21 2002-09-12 Bristol-Myers Squibb Company Nucleic acid molecules and polypeptides for a human cation channel polypeptide
DE10131786A1 (de) * 2001-07-04 2003-01-16 Sungene Gmbh & Co Kgaa Rekombinationssysteme und Verfahren zum Entfernen von Nukleinsäuresequenzen aus dem Genom eukaryotischer Organismen
AU2002353934A1 (en) * 2001-10-31 2003-05-12 Oxford Glycosciences (Uk) Ltd. Biomarkers of liver function
AU2002360986A1 (en) * 2001-12-20 2003-07-09 Sungene Gmbh And Co. Kgaa Methods for the transformation of vegetal plastids
US20060078552A1 (en) 2002-03-15 2006-04-13 Sylvain Arnould Hybrid and single chain meganucleases and use thereof
WO2009095742A1 (en) † 2008-01-31 2009-08-06 Cellectis New i-crei derived single-chain meganuclease and uses thereof
JP4966006B2 (ja) * 2003-01-28 2012-07-04 セレクティス カスタムメイドメガヌクレアーゼおよびその使用
US7888121B2 (en) * 2003-08-08 2011-02-15 Sangamo Biosciences, Inc. Methods and compositions for targeted cleavage and recombination
EP1591521A1 (de) * 2004-04-30 2005-11-02 Cellectis I-Dmo I -Derivate mit erhöhter Aktivität bei 37 Grad C und deren Verwendung
EP2484758B1 (de) † 2005-10-18 2013-10-02 Precision Biosciences Rational konstruierte Meganukleasen mit veränderter Sequenzspezifität und DNA-Bindungsaffinität
CA2691440A1 (en) † 2007-06-29 2009-01-08 Pioneer Hi-Bred International, Inc. Methods for altering the genome of a monocot plant cell
EP3098309B1 (de) † 2007-10-31 2019-04-10 Precision Biosciences, Inc. Rational konstruierte einzelketten-meganukleasen mit nicht-palindrom-erkennungssequenzen
WO2009074842A1 (en) † 2007-12-13 2009-06-18 Cellectis Improved chimeric meganuclease enzymes and uses thereof

Also Published As

Publication number Publication date
DE60316124T3 (de) 2018-03-22
CA2479153A1 (en) 2003-09-25
EP1485475B2 (de) 2017-09-20
DK1485475T3 (da) 2008-01-21
JP2011188867A (ja) 2011-09-29
JP2010207234A (ja) 2010-09-24
WO2003078619A1 (en) 2003-09-25
AU2003215869B2 (en) 2008-04-24
ES2292994T3 (es) 2008-03-16
US20040002092A1 (en) 2004-01-01
DE60316124T2 (de) 2008-06-05
EP1485475A1 (de) 2004-12-15
US20060078552A1 (en) 2006-04-13
EP1485475B1 (de) 2007-09-05
AU2003215869A1 (en) 2003-09-29
CA2479153C (en) 2015-06-02
US8206965B2 (en) 2012-06-26
JP2005520519A (ja) 2005-07-14
DE60316124D1 (de) 2007-10-18

Similar Documents

Publication Publication Date Title
ATE372379T1 (de) Hybride and einzelkettige meganukleasen und deren anwendungen
KR102212257B1 (ko) 드 노보 합성된 핵산 라이브러리
HRP20200523T1 (hr) Sastavljanje dnk posredovano nukleazom
WO2004067736A3 (en) Custom-made meganuclease and use thereof
ATE494370T1 (de) Vektoren auf transposonbasis und verfahren zur integration von nukleinsäuren
WO2018191715A3 (en) Polypeptides with type v crispr activity and uses thereof
Jurkowska et al. Mechanisms and biological roles of DNA methyltransferases and DNA methylation: from past achievements to future challenges
Lebedeva et al. The mechanism of human tyrosyl-DNA phosphodiesterase 1 in the cleavage of AP site and its synthetic analogs
MXPA05001239A (es) Secuencias de acidos nucleicos de diacilglicerol aciltransferasa y productos asociados.
WO2006036739A3 (en) Gene silencing
NO20084488L (no) Methods for the production of functional protein from DNA having a nonsense mutation and the treatment of disorders associated therewith
ATE536415T1 (de) Klonierung des cytochrome p450 gens von nicotiana
ATE335086T1 (de) Künstliche chromosomen, die die genetische information für die bildung von rekombinantem virus enthalten
HUP0303517A2 (hu) Hímfertilitást közvetítő nukleotidszekvenciák és alkalmazásuk
SG11201809242VA (en) Method for increasing mutation introduction efficiency in genome sequence modification technique, and molecular complex to be used therefor
EA201070229A1 (ru) Нуклеотидные последовательности msca1, влияющие на мужскую фертильность растений, и способ их применения
WO2003035842A3 (en) Hybridization control of sequence variation
BR0309766A (pt) Promotores usp semente especìficos para expressar genes em vegetais
SE9503117D0 (sv) Novel use of padlock probes
Ranzau et al. Genome, epigenome, and transcriptome editing via chemical modification of nucleobases in living cells
NO20005586D0 (no) Genomiske sekvenser oppströms for den kodende regionen til G- CSF genet for produksjon og levering av protein
GB2421950B (en) Method of mutagenesis
WO2003008572A8 (en) Methods of creating genetic diversity
WO2008133749A3 (en) Antimicrobial agents from microbial genomes
ATE462008T1 (de) Verfahren und mittel zur regulation der genexpression

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1485475

Country of ref document: EP